Skip Navigation

COVID-19 Update

Find a Doctor

Find a Researcher

Researchers

Tanguy Y Lim-Seiwert, M.D.

Photo of Dr. Tanguy Y Lim-Seiwert, M.D.
  • Director, Head and Neck Cancer Oncology Disease Group
  • Assistant Professor of Oncology

Languages: English, French, German

Expertise

Head and Neck Cancers

Research Interests

Immunologic Profiling; Genomic Profiling

Background

Dr. Tanguy Seiwert is an oncologist in Baltimore, caring for patients with head and neck cancer. He serves as the director of the Head and Neck Cancer Oncology Disease Program and the co-director of the Bloomberg~Kimmel Institute for Immunotherapy at the Head and Neck Cancer Program at the Johns Hopkins School of Medicine.

Dr. Seiwert earned his M.D. at Johannes Gutenberg Universität in Mainz, Germany. He completed his residency at the Duke University School of Medicine and performed a fellowship in hematology/oncology at the University of Chicago Medicine Mitchell Hospital-Hyde Park. Dr. Seiwert joined the Johns Hopkins faculty in 2009. 

Prior to joining Johns Hopkins, Dr. Seiwert was director of the Head and Neck Cancer Program at the University of Chicago. 

Dr. Seiwert’s research interests include immunologic and genomic profiling. He has given numerous invited talks on head and neck cancer both nationally and internationally. 

Dr. Seiwert serves as chief editor for Frontiers in Head and Neck Cancer and as an editorial board member for the Journal of Clinical Oncology and Oral Oncology. He is a reviewer for multiple medical journals, including Lancet Oncology, Annals of Oncology and Clinical Cancer Research. He has been recognized by the American Association for Clinical Oncology for multiple Merit Awards and a Young Investigator Award. He is also a member of the NCI Head and Neck Cancer Steering Committee, the American Association for Clinical Oncology, the Society for Immunotherapy of Cancer, the American Association for Cancer Research and the European Society of Clinical Oncology.

...read more

Titles

  • Director, Head and Neck Cancer Oncology Disease Group
  • Co-Director Bloomberg~Kimmel Institute for Immunotherapy/HNC Program
  • Assistant Professor of Oncology
  • Assistant Professor of Otolaryngology - Head and Neck Surgery

Departments / Divisions

Centers & Institutes

Education

Degrees

  • MD, Johannes Gutenberg Universitat Mainz (1999)

Residencies

  • Duke University School of Medicine / Internal Medicine (2003)

Fellowships

  • University of Chicago Medicine Mitchell Hospital-Hyde Park (2007)

Board Certifications

  • American Board of Internal Medicine / Medical Oncology (2007)

Research & Publications

Selected Publications

Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, Riaz N, Vermorken JB, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Annals of Oncology. 2018 Nov 8. [Epub ahead of print] PMID: 30407504

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. 2018 Oct 12;362(6411)

Saloura V, Fatima A, Zewde M, Kiyotani K, Bisson R, Park JH, Ikeda Y, Vougiouklakis T, Bao R, Khattri A, Seiwert TY, Cipriani N, Lingen M, Vokes EE, Nakamura Y; Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. Clinical Cancer Rearch 2017 Aug 15;23(16):4897-4907. doi:10.1158/1078-042.CCR-17-0103. Epub 2017 Apr 25. PMID: 28442504

Kadri S, Long BC, Mujacic I, Zhen CJ, Wurst MN, Sharma S, McDonald N, Niu N, Benhamed S, Tuteja JH, Seiwert TY, White KP, McNerney ME, Fitzpartrick C, Wang YL, Furtado LV, Segal JP; Clinical Validation of a Next-Generation Sequencing Genomic Oncology Panel via Cross-Platform Benchmarking against Established Amplicon Sequencing Assays. J Mol Diagn. 2017 Jan; 19(1):43-56. doi: 10.1016/j.jmoldx.2016.07.012. Epub 2016 Nov 9. PMID: 27836695

Yearley JH, Gibson C, Yu N, Moon C, Murphy E, Juco J, Lunceford J, Cheng J, Chow LQM, Seiwert TY, Handa, Tomassini JE, McClanahan T.; PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research 2017 Jun 15;23(12):2158-3167. doi: 10.1158-0432.CCR-16-1761 PMID: 28619999

Activities & Honors

Honors

  • Invited Wharton Professor/Lecturer – Yearly Wharton Research Retreat, The University of Toronto / Princess Margaret Cancer Center, Toronto, Canada, 2016
  • Travel award for the ASTRO/ASCO/AHNS Multidisciplinary Head and Neck Cancer Symposium; Palm Springs, CA: The Receptor Tyrosine Kinase c-MET as a Novel Therapeutic Target in Head and Neck Cancer, 2007
  • International Association for the Study of Lung Cancer (IASLC) Fellowship Award, The role of Heat Shock Protein 27 as a novel therapeutic target in Lung Cancer,” 2-year research funding, 2007
  • ASCO Merit Award: pKDR/KDR ratio as a possible predictor of response in a Phase I/II study of erlotinib and bevacizumab for recurrent or metastatic Head and Neck Cancer, 2007
  • ASCO Young Investigator Award: Heat Shock Protein 27 – a potential prognostic marker and therapeutic target for Non-small Cell Lung Cancer, 2006
  • ASCO Merit Award: A phase I study of Bevacizumab (B) with Fluorouracil (F) and Hydroxyurea (H) with concomitant Radiotherapy (X) - B-FHX for poor prognosis head and neck cancer (HNC), 2006
  • CALGB Fellowship Award: The role of HSP70 and HSP27 in lung cancer, 2005
  • Travel award for the 5th Annual Targeted Therapies for the Treatment of Lung Cancer Conference, Steamboat, Colorado: The role of Heat Shock Proteins as novel treatments for Lung Cancer, 2005
  • Barton F. Haynes research award (Duke University Hospital) for resident-initiated research protocol: Effects of portable Ultrasound on resident central line insertion skills and procedural learning; a randomized controlled trial, 2002

Memberships

  • NCI Head and Neck Cancer Steering Committee, 2017
  • American Association for Clinical Oncology (ASCO), 2017
  • Society for Immunotherapy of Cancer (SITC), 2017
  • American Association for Cancer Research (AACR), 2017
  • European Society of Clinical Oncology (ESMO), 2017
  • Fellow, Institute for Genomics and Systems Biology, The University of Chicago, 2013
  • University of Chicago Phase II Consortium & Personalize Cancer Care Consortium (PCCC) – Disease Oriented Group leader for Head and Neck Cancer, 2013
  • Molecular Pathology Group Member - Development NGS cancer profiling assays, 2013
  • Present Clinical Trials Review Committee (CTRC), The University of Chicago Comprehensive Cancer Center, 2012
  • The Cancer Genome Atlas (TCGA)(NCI), Head and Neck Cancer Project Data Analysis / Writing Group, 2012

Professional Activities

  • Chief editor, Frontiers in Head and Neck Cancer

Videos & Media

Treatment of HPV-Related Head and Neck Cancers

HPV-Related Head and Neck Cancers: An Overview

Patient Ratings & Comments

The Patient Rating score is an average of all responses to physician related questions on the national CG-CAHPS Medical Practice patient experience survey through Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score. Comments are also gathered from our CG-CAHPS Medical Practice Survey through Press Ganey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

  • ...Loading ratings...
  • ... 
  • ... 
  • ... 
  • ... 
  • ... 

Comments

Loading...
Is this you? Edit Profile
back to top button